Health
STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Publication: STAT
Author: Jason Mast
Source published: 16/11/2026, 10:00:00 UTC
Briefing created: 16/11/2026, 10:07:37 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 16/11/2026, 10:06:56 UTC.
Briefings
Eli Lilly and Versant Ventures invested $100 million into Seawolf Therapeutics to develop non-viral gene delivery methods, addressing the single-dose antibody response and high-dose side effects associated with current viral therapies. Sanofi partnered with the startup, and the investment occurred in November 2026, though the specific clinical trial outcomes and long-term efficacy data remain unconfirmed.
Key points
- Eli Lilly and Versant Ventures invested $100 million into Seawolf Therapeutics to develop non-viral gene delivery methods.
- Viruses are currently used in hundreds of trials for rare diseases but face drawbacks like single-dose antibody responses and high-dose side effects.
Context
Gene therapy trials using viruses have been tested in hundreds of trials for rare diseases, but viruses present drawbacks such as single-dose antibody responses and high-dose side effects. This investment aims to solve these challenges.
Limitations
Specific clinical trial outcomes and long-term efficacy data remain unconfirmed. The investment occurred in November 2026, but the specific results of the new non-viral delivery methods are not yet available.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 16/11/2026, 10:07:37 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeic2zs7og63lpzub3pvuxckbot74uicgw2aa7q4eq5sujxgh2hahja